Anna M Szpurka

7PUBLICATIONS
94CO-AUTHORS
Molecular targetsPredictive and prognostic markersSolid tumoursPharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

James J Harding, Do-Youn Oh, Teresa Macarulla Mercade

|Apr 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.

Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura

|Jan 31, 2025
Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples.

Cloud P Paweletz, Alison Urvalek, Minh Ha

|Jun 29, 2023
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma.

Patrick Schöffski, Rastislav Bahleda, Andrew J Wagner

|Apr 01, 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.

Christopher J Sweeney, Ivor J Percent, Sunil Babu

|Sep 01, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors.

Antoine Hollebecque, Hyun C Chung, Maria J de Miguel

Pageof 2

Frequent Collaborators

2 joint publications

Antoine Hollebecque

2 joint publications

Geoffrey R Oxnard

1 joint publications

Matthew D Hellmann

1 joint publications

Nicoletta Bivi